Journal article
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis
Abstract
BackgroundThe Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) double blind randomized trial demonstrated that weekly subcutaneous dulaglutide 1.5 mg, a glucagon like peptide-1 receptor agonist, versus matched placebo reduced the first outcome of major adverse cardiovascular event (MACE), cardiovascular death, nonfatal myocardial infarction or nonfatal stroke (594 versus 663 events) in 9901 persons with type 2 …
Authors
Dagenais GR; Rydén L; Leiter LA; Lakshmanan M; Dyal L; Probstfield JL; Atisso CM; Shaw JE; Conget I; Cushman WC
Journal
Cardiovascular Diabetology, Vol. 19, No. 1,
Publisher
Springer Nature
Publication Date
December 2020
DOI
10.1186/s12933-020-01179-1
ISSN
1475-2840
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AgedCardiovascular DiseasesDiabetes Mellitus, Type 2Double-Blind MethodFemaleGlucagon-Like PeptidesHeart Disease Risk FactorsHumansHypoglycemic AgentsImmunoglobulin Fc FragmentsIncretinsMaleMiddle AgedRecombinant Fusion ProteinsRisk AssessmentTime FactorsTreatment OutcomeGlucagon-Like Peptide-1 Receptor Agonists